GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that
preclinical research on two of its drug candidates, uproleselan and
GMI-1359, will be shared at the American Association for Cancer
Research (AACR) Annual Meeting 2020, which will now be held
virtually from June 22-24.
During the June session, GlycoMimetics will present preclinical
data that further support the potential of the Company’s compounds
to be used in the treatment of acute myeloid leukemia (AML) as well
as in the setting of stem cell transplantation. Additionally, new
information will be presented on the ability of transcriptome
profiling to identify those tumor types most likely to benefit from
targeted E-selectin inhibition, a key mechanism of GlycoMimetics
drug candidates, supporting their potential uses in a
biomarker-driven approach.
Important findings from the preclinical research include:
- Co-targeting and inhibition of
E-selectin/CXCR4/FLT3 with GMI-1359 in combination with sorafenib
exerts protection of normal hematopoiesis (blood cell formation)
and more efficiently reduces leukemic burden compared to sorafenib
alone, resulting in extended overall survival, in a patient-derived
FLT3 resistant AML model;
- Inhibition of E-selectin with uproleselan
during pre-transplant conditioning results in increased survival of
mice in a hematopoietic stem cell transplantation and
reconstitution model; and,
- Further analysis of E-selectin
glycosylation genes extends the prognostic importance of this
unique gene signature in AML, highlighting the potential use of
uproleselan in AML and other hematologic malignancies.
“We look forward to presenting data at this year’s AACR meeting
that will support our approach to targeting E-selectin with both
uproleselan and GMI-1359 as part of potential treatment regimens
for patients with AML and other diseases,” said John Magnani,
Ph.D., GlycoMimetics Senior Vice President and Chief Scientific
Officer. “Furthermore, the new data around glycosylation gene
signatures highlights a potential biomarker-driven approach in
targeting E-selectin.”
Of note, data will be presented demonstrating that lethality of
the FLT-3 mutation is specifically dependent upon high levels of
E-selectin ligand expressed on the surface of AML blasts. FLT-3 ITD
AML patients are known to express higher levels of E-selectin on
the vasculature endothelium. In the patient data to be reported at
the AACR meeting, patients who had the FLT-3 ITD mutation, but
presented low levels of E-selectin ligand on their AML cells, did
not experience worse outcomes, whereas those who did have FLT-3 ITD
with high levels of E-selectin ligand, experienced poor survival.
This adds support to the key role of E-selectin ligand in
contributing to poor outcomes in AML and to the potential of
uproleselan to improve AML treatment.
Details on GlycoMimetics' presentations at the upcoming virtual
AACR meeting include:
- Abstract Control #7924/ Permanent Abstract #5867:
“Transcriptome profiling of ST3GAL4 and FUT7
in multiple tumor types and prognostic value in adult acute myeloid
leukemia”
Session Type: Poster Session
Session Category: Molecular and
Cellular Biology / Genetics
Session Title: Functional Genomics and
Other Topics
- Abstract Control #3865/ Permanent Abstract #486:
“Enhanced survival of lethally-irradiated
mice with HSC reconstitution in combination with the E-selectin
antagonist, GMI-1271 (uproleselan)”
Session Type: Poster Session
Session Category: Tumor Biology
Session Title: Stem Cells, Cancer Stem
Cell Therapeutic Targeting, and Regenerative Medicine
“Combined Targeting of E-selectin/CXCR4 and
FLT3 by GMI-1359 and Sorafenib Effectively Reduces Leukemia Cell
Burden and Protects Normal Hematopoiesis in a Patient-derived AML
Xenograft Model”
Session Type: Poster Session
Session Category: Tumor Biology
Session Title: Drug Targets in the
Microenvironment
Meeting abstracts are available at AACR's website.
About Uproleselan
Discovered and developed by GlycoMimetics, uproleselan and
GMI-1687 are investigational, first-in-class, targeted inhibitors
of E-selectin. Uproleselan (yoo’ pro le’ sel an), currently in a
comprehensive Phase 3 development program in AML, has received
Breakthrough Therapy Designation from the U.S. FDA for the
treatment of adult AML patients with relapsed or refractory
disease. Uproleselan is designed to block E-selectin (an adhesion
molecule on cells in the bone marrow) from binding with blood
cancer cells as a targeted approach to disrupting well-established
mechanisms of leukemic cell resistance within the bone marrow
microenvironment. In a Phase 1/2 clinical trial, uproleselan was
evaluated in both newly diagnosed elderly and relapsed or
refractory patients with AML. In both populations, patients treated
with uproleselan together with standard chemotherapy achieved
better-than-expected remission rates and overall survival compared
to historical controls, which have been derived from results from
third-party clinical trials evaluating standard chemotherapy, as
well as lower-than-expected induction-related mortality rates.
Treatment in these patient populations was generally
well-tolerated, with fewer than expected adverse effects.
About GMI-1359
GMI-1359 is designed to simultaneously inhibit both E-selectin
and CXCR4. E-selectin and CXCR4 are both adhesion molecules
involved in tumor trafficking and metastatic spread. Preclinical
studies indicate that targeting both E-selectin and CXCR4 with a
single compound could improve efficacy in the treatment of cancers
that involve the bone marrow such as AML and multiple myeloma or in
solid tumors that metastasize to the bone, such as prostate cancer
and breast cancer, as well as in osteosarcoma, a rare pediatric
tumor. GMI-1359 has completed a Phase 1 clinical trial in healthy
volunteers. The Duke University Phase 1b clinical study in breast
cancer patients is designed to enable investigators to identify an
effective dose of the drug candidate and to generate initial
biomarker data around the drug’s activity. GMI-1359 has received
Orphan Drug Designation and Rare Pediatric Disease Designation from
the FDA for the treatment of osteosarcoma, a rare cancer affecting
about 900 adolescents a year in the United States.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company focused
on the discovery and development of novel glycomimetic drugs to
address unmet medical needs resulting from diseases in which
carbohydrate biology plays a key role. GlycoMimetics’ drug
candidate, uproleselan, an E-selectin antagonist, was evaluated in
a Phase 1/2 clinical trial as a potential treatment for AML and is
being evaluated across a range of patient populations including a
Company-sponsored Phase 3 trial in relapsed/refractory AML.
GlycoMimetics has also completed a Phase 1 clinical trial with
another wholly-owned drug candidate, GMI-1359, a combined CXCR4 and
E-selectin antagonist. GlycoMimetics is located in Rockville, MD in
the BioHealth Capital Region. Learn more at
www.glycomimetics.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding
the clinical development and potential benefits and impact of the
Company’s drug candidates. These forward-looking statements include
those relating to the planned clinical development of the Company’s
wholly-owned product candidates. Actual results may differ
materially from those in these forward-looking statements. For a
further description of the risks associated with these statements,
as well as other risks facing GlycoMimetics, please see the risk
factors described in the Company’s annual report on Form 10-K filed
with the U.S. Securities and Exchange Commission (SEC) on February
28, 2020, and other filings GlycoMimetics makes with the SEC from
time to time. Forward-looking statements speak only as of the date
of this release, and GlycoMimetics undertakes no obligation to
update or revise these statements, except as may be required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200515005324/en/
GlycoMimetics: Investor: Shari Annes Phone: 650-888-0902
Email: sannes@annesassociates.com Media: Jamie Lacey-Moreira Phone:
410-299-3310 Email: jamielacey@presscommpr.com
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Mar 2024 to Apr 2024
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Apr 2023 to Apr 2024